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Ventilator-induced lung injury (VILI) is associated with inhibition of the ﬁbrinolytic system secondary to increased production of
plasminogen activator inhibitor- (PAI-)1. To determine the role of PAI-1 on pulmonary coagulopathy and inﬂammation during
mechanical ventilation, PAI-1 gene-deﬁcient mice and their wild-type littermates were anesthetized (control), or anesthetized,
tracheotomizedandsubsequentlyventilatedfor5hourswitheitherlowtidalvolumes(LVT)orhightidalvolumes(HVT).VILIwas
assessed by pulmonary coagulopathy, lung wet-to-dry ratios, total protein level in bronchoalveolar lavage ﬂuid, neutrophil inﬂux,
histopathology, and pulmonary and plasma cytokine levels. Ventilation resulted in pulmonary coagulopathy and inﬂammation,
withmoreinjuryfollowingventilationwithHVT ascomparedtoLVT.InPAI-1gene-deﬁcientmice,theinﬂuxofneutrophilsinthe
pulmonarycompartmentwasattenuated,whileincreasedlevelsofpulmonarycytokineswerefound.OtherendpointsofVILIwere
not diﬀerent between PAI-1 gene-deﬁcient and wild-type mice. These data indicate that a defect ﬁbrinolytic response attenuates
recruitment of neutrophils in VILI.
1.Introduction
Next to alveolar tissue factor-mediated thrombin generation
and impaired activity of endogenous inhibitors of coag-
ulation, depressed alveolar ﬁbrinolysis is a typical feature
of pneumonia and acute lung injury (ALI) [1, 2]. Early
mediators of ﬁbrinolysis are plasminogen activators (PAs),
which activate plasminogen into plasmin, a potent protease
that degrades ﬁbrin into ﬁbrin degradation products. PAs
are controlled by speciﬁc inhibitors, of which plasmino-
gen activator inhibitor type 1 (PAI-1) is considered most
important, inactivating both urokinase-type PA (uPA) and
tissue-type PA (tPA). The pulmonary compartment is an
important site of PAI-1 production and activity. Elevated
bronchoalveolar lavage ﬂuid (BALF) PAI-1 levels correlate
with increased morbidity and mortality of patients suﬀering
from pneumonia [3, 4]o rA L I[ 5]. A potential role of PAI-1
inthepathogenesisoflunginﬂammationisfurthersuggested
by its upregulation in various experimental models of ALI
[6, 7] and by the ﬁnding that mice genetically deﬁcient in
PAI-1 fail to accumulate alveolar ﬁbrin and die less early in
response to hyperoxia [8].
There is compelling evidence from observations in
humans and in experimental models that neutrophils are2 Critical Care Research and Practice
primary perpetrators of inﬂammatory injury to the lung.
Indeed, neutrophil inﬂux into the alveolar space correlates
with lung injury as manifest, by an increase in permeability
of the alveolocapillary membrane [9]. In addition, in models
ofALIneutrophildepletionisprotective[10,11].Duringand
after the translocation of neutrophils from the vasculature
into the airspaces, excessive and/or prolonged activation
leads to extracellular release of soluble mediators, including
elastase, matrix metalloproteinases, defensins, and oxidants
[12]. These mediators all induce epithelial cell apoptosis
and sloughing, resulting in enhanced permeability of the
alveolocapillary membrane, which allows for extravasation
of plasma into the alveolar spaces leading to compromised
gas exchange and diminished lung compliance.
Several studies indicate that the ﬁbrinolytic system may
inﬂuence pulmonary inﬂammation. First, mice lacking the
receptor for uPA, which is expressed on diﬀerent inﬂamma-
tory cells, have an impaired leukocyte migration [13, 14].
Second, PAI-1 may aﬀect neutrophil traﬃcking in several
ways. Indeed, PAI-1 is not only an inhibitor of uPA in the
lung but can also interfere with cell adhesion in a more direct
way[15,16]. Additional evidencesupporting a role forPAI-1
incellmigrationcomesfromtumorcellbiologywhichshows
that high expression of PAI-1 is predictive of more aggressive
localinvasionandmetastasisandisapoorprognosticmarker
[17–19].
Mechanical ventilation (MV) with potentially injurious
ventilator settings (high tidal volumes (VT) and no positive
end-expiratory pressure (PEEP)) induces upregulation of
PAI-1 in the pulmonary compartment in patients without
preexisting lung injury [20]. These ﬁndings are conﬁrmed
in experimental models of ventilator-induced lung injury
(VILI) in which high VT attenuate alveolar ﬁbrinolytic
activity [21, 22]. This appears to be caused, at least in
part, by increased local production of PAI-1. Inﬁltration of
neutrophilsconcomitantwiththedevelopmentofphysiolog-
ical signs of lung injury is a characteristic feature of VILI
[23–25]. The direct relation between local PAI-1 activity
and neutrophil inﬁltration during VILI, however, has never
been elucidated. Therefore, the main objective of this study
was to determine the role of endogenous PAI-1 in alveolar
coagulopathy and pulmonary inﬂammation, in particular
neutrophil inﬁltration, in response to mechanical ventila-
tion. For this, we used an MV model in mice comparing low
and high VT, using PAI-1 gene-deﬁcient (PAI-1−/−)m i c e .
2.MaterialsandMethods
The study was approved by the Animal Care and Use
Committee of the Academic Medical Center of the Univer-
sity of Amsterdam, Amsterdam, The Netherlands. Animal
procedures were carried out in compliance with Institutional
Standards for Human Care and Use of Laboratory Animals.
2.1. Animals. PAI-1 gene-deﬁcient (PAI-1−/−)m i c eo na
C57Bl/6 genetic background (n = 36) and normal C57Bl/6
wild-type (Wt) mice (n = 36) were obtained from the
JacksonLaboratory(BarHarbor,ME).PAI-1−/− miceexhibit
normal fertility, viability, tissue histology, and development
and show neither evidence of macroscopic or microscopic
histological abnormalities nor hemorrhage [26]. Female
mice with weights ranging from 18 to 22 grams were used
in all experiments. Nonventilated anesthetized mice served
as controls (n = 12 for PAI-1−/− mice and Wt mice).
Tracheotomized mice were connected to a ventilator and
ventilated with 2 diﬀerent MV strategies (n = 12 for PAI-
1−/− mice and Wt mice for every diﬀerent MV strategy).
2.2. Instrumentation and Anesthesia. Anesthesia consisted
of intraperitoneal injection of a mix of ketamine (Eurovet
Animal Health BV, Bladel, the Netherlands), medetomidine
(Pﬁzer Animal Health BV, Capelle a/d IJssel, The Nether-
lands), and atropine (Pharmachemie, Haarlem, the Nether-
lands) (KMA). Induction anesthesia was achieved with
intraperitoneal injection of KMA “induction” mix: 7.5μL
per gram of body weight of 1.26mL 100mg/mL ketamine,
0.2mL 1mg/mL medetomidine, and 1mL 0.5mg/mL
atropine in 5mL normal saline. Maintenance anesthesia
was achieved with hourly intraperitoneal injection of 10μL
per gram body weight of KMA “maintenance” mix, con-
sisting of 0.72mL 100mg/mL ketamine, 0.08mL 1mg/mL
medetomidine, and 0.3mL 0.5mg/mL atropine, in 20mL
normal saline. Maintenance mix was administered via an
intraperitoneal catheter (PE 10 tubing, BD, Breda, The
Netherlands) every hour.
2.3. Mechanical Ventilation. AY - t u b ec o n n e c t o r ,1 . 0 m m
outer diameter and 0.6mm inner diameter (VBM Medizin-
technik GmbH, Sulz am Neckar, Germany), was surgically
inserted into the trachea under general anesthesia. Mice were
placed in a supine position and connected to a ventilator
(Servo 900C, Siemens, Sweden). Mice were ventilated with
either an inspiratory pressure of 10cmH2O (resulting in
lung-protective VT ∼ 7.5mL/kg; low VT,L V T)o ra n
inspiratory pressure of 18cmH2O (resulting in injurious
VT ∼ 15mL/kg; high VT,H V T). Respiratory rate was set
at 120breaths/min and 70breaths/min with LVT and HVT,
respectively. PEEP was set at 2cmH2Ow i t hb o t hM V
strategies. Respiratory settings resulted in normal PaCO2
v a l u e sa f t e r5ho fM Vw i t hb o t hs t r a t e g i e s[ 27]. The fraction
of inspired oxygen was kept at 0.5. The inspiration to
expiration ratio was kept at 1:1 throughout the experiment.
A sigh (sustained inﬂation with 30cmH2O) for 5 breaths was
performed every 30 minutes. Mice received intraperitoneal
ﬂuid boluses (normal saline 1 hour before start of anesthesia
andinitiationofMV,followedby0.2mLsodiumbicarbonate
(200mmol/L NaHCO3) administered via the intraperitoneal
catheter every 30 minutes until the end of MV).
2.4. Monitoring. Throughout the experiments rectal tem-
perature was monitored and maintained between 36.0 and
37.5◦C using a warming path. Systolic blood pressure and
heart rate were noninvasively monitored using a murine tail-
cuﬀ system (ADInstruments, Spenbach, Germany). Blood
pressure and pulse were measured directly after start of MV,
after 2.5 and 5 hours of MV. The data were recorded onCritical Care Research and Practice 3
a data acquisition system (PowerLab/4SP, ADInstruments).
Systolic blood pressure and heart rate were averaged from
3 consecutive measurements. VT was checked hourly with
a plethysmograph system. A minimum of 5 consecutive
breaths was selected for analysis of the digitized VT signals.
2.5. Study Groups. Nonventilated mice received half the
dose of induction anesthesia, were spontaneously breathing,
and sacriﬁced after 5 hours (control mice). LVT mice and
HVT-mice were mechanically ventilated for 5 hours and
then sacriﬁced. Half of these mice were sacriﬁced for blood
sampling, drawn from the vena cava inferior into a sterile
syringe, transferred to EDTA-coated tubes, and immediately
placed on ice. Subsequently, bronchoalveolar lavage ﬂuid
(BALF) was obtained from the right lung; the left lung was
used to measure wet-to-dry ratios (W/D). The other half of
these mice were sacriﬁced for blood gas analysis, and blood
was sampled from the carotid artery. The lungs of these mice
were used for homogenate (right lung) and histopathology
(left lung).
2.6. Blood Gas Analysis and Blood Sample Handling. For
blood gas analysis, blood was immediately analyzed in a
Rapidlab 865 blood gas analyzer (Bayer, Mijdrecht, The
Netherlands). The other blood samples were centrifuged
at 3000rpm at 4◦C for 10min, and the supernatants were
aliquoted and frozen at −80◦C until assayed.
2.7. Lung Wet-to-Dry Ratios (W/D). For W/D the left lung
was weighed and subsequently dried for 3 days in an oven at
65◦C. The ratio of wet weight to dry weight represents tissue
edema.
2.8. Bronchoalveolar Lavage. BALF was obtained from the
right lung by instilling three times 0.5mL aliquots of saline
by a 22-gauge Abbocath-T catheter (Abbott, Sligo, Ireland)
into the trachea. Approximately, 1.1mL of lavage ﬂuid
was retrieved per mouse, and cell counts were determined
using a hemacytometer (Beckman Coulter, Fullerton, Calif).
Subsequently, diﬀerential counts were done on cytospin
preparations stained with a modiﬁed Giemsa stain, Diﬀ-
Quick (Dade Behring AG, D¨ udingen, Switzerland). Super-
natant was stored at −80◦C for total protein level, thrombin-
antithrombin complexes, and PAI-1 levels.
2.9. Lung Homogenates. During sacriﬁcing the right lung
was removed and snap frozen in liquid nitrogen. Lung
homogenates were prepared as described before [28]. In
short, frozen specimens were weighed and suspended in
4 volumes of sterile isotonic saline and subsequently
lysed in 1 volume of lysis buﬀer (150mM NaCl, 15mM
Tris[tris(hydroxymethyl)aminomethane],1mMMgCl.H2O,
1mM CaCl 2, 1% Triton X-100, 100μg/mL pepstatin A,
leupeptin and aprotinin, pH 7.4) and incubated at 4◦Cf o r
30min. Homogenates were spun at 3400rpm at 4◦Cf o r1 5
minutes after which the supernatants were stored at −80◦C
until assayed.
2.10. Histopathology. For histopathology lungs were ﬁxed
in 4% formalin and embedded in paraﬃn. 4μms e c t i o n s
were stained with hematoxylin-eosin (H&E), and analyzed
by a pathologist who was blinded for group identity. To
score lung injury we used a modiﬁed VILI histology scoring
systemaspreviouslydescribed[23].Inshort,fourpathologic
parameters were scored on a scale of 0–4: (a) alveolar
congestion, (b) hemorrhage, (c) leukocyte inﬁltration, and
(d) thickness of alveolar wall/hyaline membranes. A score of
0 represents normal lungs; 1, mild, <25% lung involvement;
2, moderate, 25−50% lung involvement; 3, severe, 50–
75% lung involvement, and 4, very severe, >75% lung
involvement. The total histology score was expressed as the
sum of the score for all parameters.
2.11. PAI-1 In Situ Hybridization. PAI-1 in situ hybridization
wasperformedasdescribedbefore[29].Inshort,7-μm-thick
paraﬃns e c t i o n so fl u n gt i s s u ew e r em o u n t e do nS u p e r F r o s t
Plus glass slides (Menzel-Gl¨ aser, Braunschweig, Germany)
and subjected to in situ hybridization using radiolabeled
[35S]-UTP (Amersham, Arlington Heights, Ill, USA) mouse
PAI-1-speciﬁc riboprobes. In situ hybridization was executed
by standard procedures. In situ sections were covered with
autoradiography emulsion (Ilford G5 emulsion 1:1 diluted
with 2% glycerol). Slides were developed in Kodak D19
after an exposure of 5 weeks, ﬁxed in Kodak UNIFIX, and
counterstained with hematoxylin and eosin. Four sections
per specimen were used to conﬁrm positive PAI-1 in situ
hybridization signal.
2.12. Assays. Total protein levels in BALF were determined
using a Bradford Protein Assay Kit (OZ Biosciences, Mar-
seille, France) according to manufacturers’ instructions with
bovine serumalbumin as standard. Cytokine and chemokine
levels in lung homogenates were measured by enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer’s instructions. Tumor necrosis factor α (TNF),
interleukin- (IL-) 6, macrophage inﬂammatory protein-
(MIP-) 2, and keratinocyte-derived chemokine (KC) assays
were all obtained from R&D Systems (Abingdon, UK).
Thrombin-antithrombin complex levels in BALF were
measured with a mouse-speciﬁc ELISA as previously des-
cribed [30]. PAI-1 was measured with ELISA (Kordia,
Leiden,TheNetherlands).Tomeasureplasminactivity,levels
of ﬁbrin degradation products, the split product cleaved oﬀ
from cross-linked ﬁbrin by a direct action of plasmin, were
measuredbymeansofELISA(AsserachromD-dimer,Roche,
Woerden, The Netherlands).
2.13. Statistical Analysis. All data in the results are exp-
ressed as individual data in the ﬁgures. To detect diﬀer-
ences between mechanical ventilation groups, the Dunnett
method, in conjunction with two-way analysis of variance,
was used. For diﬀerences between PAI-1−/− and Wt mice,
post hoc analysis with Mann Whitney U test was done. A
P value of < 0.05 was considered signiﬁcant. All statistical
analyses were carried out using SPSS 12.0.2 (SPSS, Chicago,
Ill).4 Critical Care Research and Practice
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Figure 1: (a) Plasminogen activator inhibitor- (PAI-) 1 mRNA in lung. PAI-1 mRNA as determined by radioactive in situ hybridization
(autoradiographic ﬁlm). (b) PAI-1 levels in bronchoalveolar lavage ﬂuid in anesthetized nonventilated control (c) mice, mice ventilated with
low tidal volumes (LVT) and high VT (HVT). Levels of PAI-1 in PAI-1−/− mice were undetectable. Data are represented as individual data
with a median. In situ hybridization for murine PAI-1 mRNA was performed on paraﬃn slides of nonventilated control Wt mice (c), Wt
mice ventilated with LVT (d) and HVT (e) for 5 hours. Positive signal in black. Original magniﬁcation 100x.
3. Results
Allinstrumentedanimalssurvived5hoursofMVafterwhich
they were sacriﬁced. Hemodynamic monitoring demon-
strated stable conditions throughout the experiment; systolic
blood pressure and heart rate remained stable in all animals
forthecompletedurationofMV.Bloodgasanalyseswerenot
diﬀerent between both ventilation groups and between PAI-
1−/− and Wt mice.
3.1. Production of PAI-1 with Low and High VT. To conﬁrm
P A I - 1p r o d u c t i o ni no u rm o d e l ,w em e a s u r e dP A I - 1l e v e l s
in BALF. MV increased the concentrations of PAI-1 after
5 hours of MV as compared to control mice (P<0.001
for LVT mice and HVT mice; Figure 1). To obtain insight
into the cellular source of PAI-1 in the normal and injured
lung, we performed in situ hybridization. In normal lung,
a faint signal for PAI-1 mRNA transcripts was detected
in endothelial cells as well as in bronchiolar and alveolar
epithelium (Figure 1). After 5 hours of MV, a strong
expression of PAI-1 mRNA was observed, predominantly in
vessels showing endothelial injury, in inﬂamed bronchi, in
areas of inﬂammatory inﬁltrates, and in areas of pleuritis.
3.2. Pulmonary Coagulopathy. BALF TATc levels were higher
in both ventilation groups as compared to control mice (P =
0.049 for LVT mice and P<0.001 for HVT mice), with
higher levels in HVT mice (P<0.001 versus LVT)m i c e ;
Figure 2). There was no signiﬁcant diﬀerence between PAI-
1−/− mice and Wt mice regarding activation of coagulation
in the pulmonary compartment. Levels of ﬁbrin degradationCritical Care Research and Practice 5
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Figure 2:Thrombin-antithrombincomplexes(TATcs)levelsinbronchoalveolarlavageﬂuidandlevelsofﬁbrindegradationproductsinlung
homogenate in anesthetized nonventilated control (C) mice, mice ventilated with LVT or HVT. Mice were either PAI-1 deﬁcient (PAI-1−/−,
open symbols) or wild type (Wt, closed symbols). Data are represented as individual data with a median. ∗, indicates statistical signiﬁcant
diﬀerence compared to Wt.
products were higher in both ventilated groups as compared
to control (P<0.001 for LVT mice and HVT mice), with
higher levels in HVT mice (P<0.001 versus LVT mice;
Figure 2).In PAI-1−/− mice ﬁbrinolysis wasenhancedduring
MV, as reﬂected by a stronger increase in levels of ﬁbrin
degradation products (Figure 2).
3.3. Lung Injury. Lung W/D was signiﬁcantly higher in HVT
mice as compared to LVT mice and controls (P<0.001;
Figure 3). In accordance, total BALF protein levels were
higher in both ventilation groups (P = 0.049 for LVT mice
and P<0.001 for HVT mice), with higher levels in HVT
mice (P<0.001; Figure 3). The number of neutrophils in
BALF was higher in both HVT and LVT mice as compared
to control (P<0.001 and P = 0.047, resp.). The diﬀerence
between HVT mice and LVT mice was signiﬁcant (P<0.001;
Figure 3).
No diﬀerences were seen between PAI-1−/− mice and Wt
mice regarding W/D and total protein in BALF (Figure 3).
However, in PAI-1−/− mice, there was less neutrophil inﬂux
inbothventilatedgroupsascomparedtoWtmice(P = 0.004
for LVT mice and P = 0.002 for HVT mice; Figure 3).
Histopathological changes were minor. The VILI score in
HVT mice was signiﬁcantly higher as compared to control
mice (P = 0.026). No diﬀerence in VILI score was observed
between LVT mice and HVT mice. Finally, histopathological
lung injury scores were not diﬀerent between PAI-1−/−mice
and Wt mice.
3.4. Pulmonary and Systemic Inﬂammation. Ventilated mice
demonstrated higher pulmonary levels of TNF and IL-6 as
compared to control mice (P<0.001 for LVT mice and
HVT mice). For both cytokines there was no signiﬁcant
diﬀerence between LVT and HVT mice, however (Figure 4).
Ventilated mice also demonstrated higher pulmonary levels
of MIP-2 and KC as compared to control (P<0.001 for
LVT and HVT mice), with higher levels of MIP-2 and KC in
HVT mice (P<0.001 versus LVT mice; Figure 4). PAI-1−/−
mice demonstrated higher pulmonary TNF and IL-6 levels
in nonventilated control mice (P = 0.002 and P = 0.009,
resp.; Figure 4). For both ventilated groups pulmonary TNF
and IL-6 levels were signiﬁcantly higher in PAI-1−/− mice as
compared to Wt mice. Pulmonary levels of MIP-2 and KC
were elevated in all PAI-1−/− mice, except for KC levels in the
LVT group (P = 0.13).
Plasma levels of IL-6 and KC were elevated in both
ventilation groups as compared to control (P<0.001 for
both LVT and HVT mice), with higher levels in HVT mice
(P<0.001; Figure 5). Plasma levels of IL-6 were lower in
PAI-1−/− mice in the LVT g r o u pa sc o m p a r e dt oW tm i c e
(P = 0.009; Figure 5). HVT mice demonstrated a trend for
lower IL-6 levels in PAI-1−/− mice (P = 0.065). For plasma
levels of KC, no diﬀerences were observed between PAI-
1−/−mice and Wt mice.
4. Discussion
There is mounting evidence indicating that PAI-1 plays a
potent role in the procoagulant response with various forms
oflunginjury.Theresultsfromthepresentstudysuggestthat
PAI-1 is responsible, at least in part, for neutrophil inﬂux
into the alveolar space with MV-induced lung injury, since
PAI-1−/− mice show less neutrophil inﬂux as compared to
Wt mice. On the other hand, PAI-1−/− mice show increased6 Critical Care Research and Practice
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Figure 3: Wet-to-dry ratios (W/D) of the left lung, total protein level in BALF, and number of neutrophils in BALF in anesthetized
nonventilated control (C) mice, mice ventilated with LVT or HVT. Mice were either PAI-1 deﬁcient (PAI-1−/−,o p e ns y m b o l s )o rw i l dt y p e
(Wt, closed symbols). Data are represented as individual data with a median. ∗ indicates statistical signiﬁcant diﬀerence compared to Wt.
pulmonary levels of inﬂammatory mediators, even in the
control, nonventilated mice. Plasma levels of IL-6 were lower
in PAI-1−/− mice as compared to Wt mice. Notably, PAI-1
deﬁciency did not result in changes of other endpoints of
lung injury, that is, gas exchange, W/D, BALF protein levels,
and histopathology.
PAI-1 is ﬁrst of all a strong inhibitor of ﬁbrinolysis.
In line, PAI-1−/− mice have an accelerated spontaneous
whole blood clot lysis [26]. We here show that PAI-1 is
upregulated during MV, with higher levels of PAI expression
during high tidal volume ventilation. In addition D-dimer
concentrations, as a reﬂection of ﬁbrinolysis, are elevated
during MV. In PAI-1 deﬁcient mice ﬁbrinolysis is enhanced.
Besides its role as a regulator of haemostasis by regulating
ﬁbrinolytic activity, PAI-1 plays a role in many other
(patho)physiological processes, including wound healing,
atherosclerosis, tumor angiogenesis, pulmonary ﬁbrosis, and
kidney disease [18, 19, 25, 29, 31, 32]. In addition PAI-1 acts
asanacutephaseproteinduringsepsis[33],andplasmaPAI-
1 levels rise markedly during disease states often associated
with a sterile acute phase response including trauma and
surgery [34]. More recently, PAI-1 has been shown to be
critically involved in the regulation of cell migration. PAI-1
can inhibit cell bound uPA, resulting in reduced pericellular
proteolysis and a subsequent decrease in cell migration. On
the contrary, deadhesive action of PAI-1 by inactivation ofCritical Care Research and Practice 7
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Figure 4: Pulmonary levels of tumor necrosis factor α (TNF), interleukin- (IL-) 6, macrophage inﬂammatory protein- (MIP-) 2, and
keratinocyte-derived chemokine (KC) in lung tissue homogenate in anesthetized nonventilated control (C) mice, mice ventilated with LVT
or HVT. Mice were either PAI-1 deﬁcient (PAI-1−/−, open symbols) or wild type (Wt, closed symbols). Data are represented as individual
data with a median. ∗ indicates statistical signiﬁcant diﬀerence compared to Wt.
the cell-integrin-extracellular matrix interaction may result
in an increase of cell mobility as well. So PAI-1 seems to exert
both promoting and inhibitory eﬀects on cell migration.
The direct relation between local PAI-1 activity and
neutrophil inﬁltration during VILI was recently described by
Liuetal.[35].Theyventilatedmicewitheither6or30mL/kg
and added hyperoxia. High-tidal-volume ventilation of the
mouse induced the microvascular permeability, neutrophil
inﬂux, TNF-α, and PAI-1 production. The addition of
hyperoxia augmented this deleterious eﬀect on injurious
mechanical ventilation and was dependent, at least in part,
on the NF-κB pathway. Inhibition of NF-Kβ reduced TNF-
α, PAI-1, and MPO activity in mice ventilated with high VT
and hyperoxia. Increases of PAI-1 on airway epithelium was
reduced after pretreatment with anti-TNF-α antibody which
implied that PAI-1 expression was partly induced by TNF-α.
Severalstudieswithinfectiousagentshaveshownadecreased
pulmonary neutrophil inﬂux in PAI-1−/− mice [28, 29].
Neutrophils are thought to play a predominant role during
the initiation of VILI [24, 36]. In our well-established MV
model [27, 37] we used physiological and clinically relevant
VT, which enhances translation of results into clinical
practice. Our results of attenuated neutrophil inﬂux in PAI-
1−/− mice are in line with several other reports. First, in a
Klebsiella pneumoniae pneumonia model in mice, PAI-1−/−
mice demonstrated less inﬁltrating neutrophils in their lungs8 Critical Care Research and Practice
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Figure 5: Systemic levels of interleukin- (IL-) 6, and keratinocyte-derived chemokine (KC) in plasma in anesthetized nonventilated control
(C) mice, mice ventilated with LVT or HVT. Mice were either PAI-1 deﬁcient (PAI-1−/−, open symbols) or wild type (Wt, closed symbols).
Data are represented as individual data with a median. ∗ indicates statistical signiﬁcant diﬀerence compared to Wt.
[28]. A diminished inﬂux of neutrophils into the BALF of
PAI-1−/− micehasalsobeenfoundafterlocalpulmonaryLPS
exposure [7]. Also in a mice model of acute pyelonephritis
lower neutrophil inﬂux was observed in PAI-1−/− mice as
compared to Wt mice [29]. Our ﬁndings are also in line
with the results obtained in a model of bleomycin-induced
lung injury, in which PAI-1 gene deﬁciency protected against
inﬂammation-induced lung damage and overexpression of
PAI-1 enhanced the accumulation of neutrophils in the
lung [38]. Furthermore, in an antigen-induced arthritis
model PAI-1−/− mice showed signiﬁcantly reduced joint
inﬂammation [39]. In a model of glomerulonephritis PAI-
1 deﬁciency reduced the number of inﬁltrating neutrophils
in the glomeruli, while mice overexpressing PAI-1 showed a
profound increase in neutrophil inﬁltration [40]. Our data
extend these ﬁndings by showing that neutrophil inﬁltration
is attenuated in PAI-1−/− mice in a model of VILI.
Besides less neutrophil inﬂux in PAI-1−/− mice, wefound
increased pulmonary levels of inﬂammatory cytokines, even
in the control, nonventilated mice. One explanation might
be the genetic background of transgenic animals, which can
inﬂuence diﬀerent responses. The responses of transgenic
animals to a challenge thus reﬂect the dysfunction (or
alteration of the function) of the gene of interest plus
compensatory mechanisms. It can also be hypothesized that
the cytokine levels in Wt mice peaked earlier and that
mice deﬁcient for PAI-1 show a slower pulmonary cytokine
response. In a recently published paper of Hegeman et
al. they show that the cytokine peak in the lung is after
two hours of MV in healthy mice ventilated with a peak
inspiratory pressure of 20cmH2Oa n d0c m H 2O PEEP [41].
In our study we only measured cytokine levels after 5
hours of MV. On the other hand the systemic cytokines in
PAI-1−/− are not increased as compared to Wt mice. IL-6
levels are even decreased in PAI-1−/− mice. These cytokines
will eventually be detrimental in causing multisystem organ
failure [42, 43].
Our study has several limitations, though. First, only
less neutrophil inﬂux was observed for PAI-1−/− mice as
comparedto Wt mice, with no diﬀerences in other endpoints
of VILI, such as W/D or protein leakage in BALF. Because
we used less high VT as compared to other models of
VILI, the challenge in our setting may be too mild to
observe these diﬀerences. Second, our nonventilated control
animals were not sham operated, did not receive ﬂuid
resuscitation, and were breathing room air as opposed to
our ventilated animals. One last shortcoming of our study
lies in the use of genetically modiﬁed animals. The genetic
background of transgenic animals can inﬂuence diﬀerent
responses. Indeed, when we knock out or knock down a gene
from the genome, it may trigger compensatory mechanisms.
The responses of transgenic animals to a challenge thus
reﬂect the dysfunction (or alteration of the function) of
the gene of interest plus compensatory mechanisms. The
increased level of pulmonary cytokines in PAI-1−/− mice,
even in the control, nonventilated mice, could be due to
this phenomenon. Therefore, the lack of diﬀerence for hard
endpoints of VILI (like W/D and protein leakage in BALF)
between PAI-1−/− mice and Wt mice cannot exclude the
possibility of using anti-PAI-1 therapies for VILI. Additional
studies are needed to test this hypothesis.
Recently angiotensin-converting enzyme activity was
shown to be an additional pathway regulating PAI-1 expres-
sion [44]. Administration of exogenous PAI-1 reversed the
inhibitory eﬀect of enalapril on neutrophil inﬂux to the
lung after exposure to LPS. These data strongly suggestCritical Care Research and Practice 9
that the role of PAI-1 in inﬂammatory cell migration is
often stimulatory. Neutrophil recruitment into the lung is
believed to be a critical step in the pathogenesis of ALI
and results from the release of a milieu of cytokines and
chemokines that precedes ALI [45]. Recently, it was shown
that a neutrophil elastase inhibitor could attenuate VILI
in mice. Indeed, mice that received the neutrophil elastase
inhibitor showed complete inhibition of neutrophil elastase
and myeloperoxidase activities, attenuation of neutrophil
accumulation and lung water content [46]. In another
VILI model pretreatment with a matrix metalloproteinase-
9 inhibitor resulted in a decreased degree of VILI, as reﬂected
by W/D and pathology score, and decreased neutrophil
inﬁltration [47]. Matrix metalloproteinase-9, which is pro-
duced by neutrophils and other inﬂammatory cells, plays an
important role in neutrophil migration.
Our results indicate that PAI-1 deﬁciency is associated
with less neutrophil recruitment into the lung. Also, PAI-
1 seems to be a very sensitive biomarker for detection of
ventilator-induced lung injury in our MV model as opposed
to other biomarkers measured. Elevated pulmonary PAI-1
levels correlate with poor outcome in patients with pneu-
monia [3, 4, 48]. Similarly, in ALI/ARDS elevated plasma
levels of PAI-1 are associated with increased morbidity and
mortality [5].
The value of increased pulmonary cytokines in PAI-1−/−
mice as compared to Wt mice is diﬃcult, because they
are already increased in nonventilated control mice. More
important are the lower plasma IL-6 levels in PAI-1−/−mice
as compared to Wt mice, since IL-6 can lead to multiorgan
dysfunction syndrome [43].
5. Conclusions
PAI-1 gene deﬁciency attenuates recruitment of neutrophils
into the alveolar space during mechanical ventilation. This
suggests PAI-1 to play a stimulatory role of cell migration
into the alveoli, which is independent of local production of
chemokines. PAI-1 gene deﬁciency causes lower plasma IL-6
levelseveninthepresenceofincreasedpulmonarycytokines.
PAI-1seemstobeaverysensitivebiomarkerforthedetection
of ventilator-induced lung injury and could be used for
ICU patients at risk for developing ventilator-associated lung
injury.
Further studies are needed before inhibition of PAI-1 is
to be tested in clinical trials of patients with or at risk for
ventilator-associated lung injury.
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